Literature DB >> 8991640

Specific antibody response to oligomannosidic epitopes in Crohn's disease.

B Sendid1, J F Colombel, P M Jacquinot, C Faille, J Fruit, A Cortot, D Lucidarme, D Camus, D Poulain.   

Abstract

Elevated antibody levels against the yeast Saccharomyces cerevisiae have been reported in sera from patients with Crohn's disease and not with ulcerative colitis. The aim of the study was to identify the nature of the epitopes supporting this antibody response. Whole cells from different S. cerevisiae strains were selected in immunofluorescence assay for their ability to differentiate the antibody responses of patients with Crohn's disease and ulcerative colitis. Their cell wall phosphopeptidomannans were then tested as antigen in enzyme-linked immunosorbent assay (ELISA) against sera from 42 patients with Crohn's disease, 20 patients with ulcerative colitis, and 34 healthy controls. Graded chemical degradations were performed on the most reactive strain phosphopeptidomannan. The discriminating epitope was determined through gas-liquid chromatography-mass spectrometry. The greatest discrimination among patients with Crohn's disease, ulcerative colitis, and controls was obtained with Su1, a S. cerevisiae strain used in brewing of beer. ELISA directed against phosphopeptidomannan of this strain was 64% sensitive and 77% specific for discriminating Crohn's disease versus ulcerative colitis and 71% sensitive and 89% specific for Crohn's disease versus controls. Periodate oxidation and selective degradation demonstrated that the most important polysaccharide epitope was shared by both the acid-stable and the alkali-labile domains of the phosphopeptidomannan. The determination of oligomannose sequences of S. cerevisiae Su1 phosphopeptidomannans suggested that a mannotetraose, Man (1 --> 3)Man(1 --> 2)Man(1 --> 2)Man, supported the serological response seen in Crohn's disease. Further identification of the immunogen eliciting this antibody response as a marker of the disease may help to understand its etiology.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8991640      PMCID: PMC170283          DOI: 10.1128/cdli.3.2.219-226.1996

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  42 in total

1.  Antibody (IgG, IgA, and IgM) to baker's yeast (Saccharomyces cerevisiae), yeast mannan, gliadin, ovalbumin and betalactoglobulin in monozygotic twins with inflammatory bowel disease.

Authors:  E Lindberg; K E Magnusson; C Tysk; G Järnerot
Journal:  Gut       Date:  1992-07       Impact factor: 23.059

2.  A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples.

Authors:  M A Markwell; S M Haas; L L Bieber; N E Tolbert
Journal:  Anal Biochem       Date:  1978-06-15       Impact factor: 3.365

Review 3.  Antigenic structure of Candida albicans. Immunochemical basis of the serologic specificity of the mannans in yeasts.

Authors:  Y Fukazawa
Journal:  Immunol Ser       Date:  1989

4.  On the existence of cross-reactive antigens between Candida and Mycobacterium.

Authors:  S Maekawa; T Ohara
Journal:  Jpn J Microbiol       Date:  1966-04

Review 5.  Oligosaccharide signals: from plant defense to parasite offense.

Authors:  C A Ryan
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-04       Impact factor: 11.205

6.  Gas--liquid chromatography and mass spectrometry of methylated and acetylated methyl glycosides. Application to the structural analysis of glycoprotein glycans.

Authors:  B Fournet; G Strecker; Y Leroy; J Montreuil
Journal:  Anal Biochem       Date:  1981-09-15       Impact factor: 3.365

7.  Increased intestinal permeability in patients with Crohn's disease and their relatives. A possible etiologic factor.

Authors:  D Hollander; C M Vadheim; E Brettholz; G M Petersen; T Delahunty; J I Rotter
Journal:  Ann Intern Med       Date:  1986-12       Impact factor: 25.391

8.  The effect of dietary yeast on the activity of stable chronic Crohn's disease.

Authors:  G R Barclay; H McKenzie; J Pennington; D Parratt; C R Pennington
Journal:  Scand J Gastroenterol       Date:  1992       Impact factor: 2.423

9.  Lymphocyte proliferation response to baker's yeast in Crohn's disease.

Authors:  C A Young; A Sonnenberg; E A Burns
Journal:  Digestion       Date:  1994       Impact factor: 3.216

10.  CD45RO expression on circulating CD19+ B cells in Crohn's disease correlates with intestinal permeability.

Authors:  B R Yacyshyn; J B Meddings
Journal:  Gastroenterology       Date:  1995-01       Impact factor: 22.682

View more
  62 in total

1.  Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in affected and unaffected relatives of patients with Crohn's disease.

Authors:  C L Sutton; H Yang; Z Li; J I Rotter; S R Targan; J Braun
Journal:  Gut       Date:  2000-01       Impact factor: 23.059

Review 2.  Diagnostic methodologies: serology, endoscopy, and radiology.

Authors:  T Dassopoulos
Journal:  Curr Gastroenterol Rep       Date:  2001-12

3.  Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics.

Authors:  E A Vasiliauskas; L Y Kam; L C Karp; J Gaiennie; H Yang; S R Targan
Journal:  Gut       Date:  2000-10       Impact factor: 23.059

Review 4.  Serologic testing in inflammatory bowel disease: its value in indeterminate colitis.

Authors:  K A Papadakis; S R Targan
Journal:  Curr Gastroenterol Rep       Date:  1999-12

5.  Anti-Saccharomyces cerevisiae antibodies associate with phenotypes and higher risk for surgery in Crohn's disease: a meta-analysis.

Authors:  Zhaoxia Zhang; Chen Li; Xinmei Zhao; Chaolan Lv; Qiong He; Shan Lei; Yandong Guo; Fachao Zhi
Journal:  Dig Dis Sci       Date:  2012-06-06       Impact factor: 3.199

Review 6.  Recent advances in the diagnosis and classification of inflammatory bowel disease.

Authors:  Eric Vasiliauskas
Journal:  Curr Gastroenterol Rep       Date:  2003-12

7.  Anti-saccharomyces cerevisiae IgA antibodies are raised in ankylosing spondylitis and undifferentiated spondyloarthropathy.

Authors:  I E A Hoffman; P Demetter; M Peeters; M De Vos; H Mielants; E M Veys; F De Keyser
Journal:  Ann Rheum Dis       Date:  2003-05       Impact factor: 19.103

8.  Frequency and significance of antibodies to Saccharomyces cerevisiae in autoimmune hepatitis.

Authors:  Albert J Czaja; Zakera Shums; Peter T Donaldson; Gary L Norman
Journal:  Dig Dis Sci       Date:  2004-04       Impact factor: 3.199

9.  Utility of fecal and serum anti-Saccharomyces cerevisiae antibodies in the diagnosis of Crohn's disease-like condition of the pouch.

Authors:  Linda Y Tang; Hui Cai; Udayakumar Navaneethan; James H Boone; Sarah J Rhodes; Lauren Moore; Hyunjin Rho; Carol de La Motte; Elaine Queener; Bo Shen
Journal:  Int J Colorectal Dis       Date:  2012-03-20       Impact factor: 2.571

10.  Anti-high mobility group box 1 and box 2 non-histone chromosomal proteins (HMGB1/HMGB2) antibodies and anti-Saccharomyces cerevisiae antibodies (ASCA): accuracy in differentially diagnosing UC and CD and correlation with inflammatory bowel disease phenotype.

Authors:  Hiromasa Takaishi; Takanori Kanai; Atsushi Nakazawa; Fumihiko Sugata; Akira Nikai; Shigeo Yoshizawa; Yasuo Hamamoto; Shinsuke Funakoshi; Tomoharu Yajima; Yasushi Iwao; Masao Takemura; Shoichi Ozaki; Toshifumi Hibi
Journal:  J Gastroenterol       Date:  2012-05-30       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.